AU000000TLX2
© PR Newswire
10.12.2025
TLX
LISTED
ASX
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
News Preview
MELBOURNE, Australia and PALO ALTO, Calif., Dec. 11, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinical applications that combine Telix's theranostic prod...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
TLX
LISTED
ASX
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
News Preview
MELBOURNE, Australia and PALO ALTO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinical applications that combine Telix’s theranostic...
Themefolio
Profiler
Peergroup
© PR Newswire
07.12.2025
TLX
LISTED
ASX
ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate TLX591 (lutetium (177Lu) rosop...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
19.11.2025
TLX
LISTED
ASX
ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Nov. 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®[1], 89Zr-DFO-girentuximab) PET/CT[2] would have undergon...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
19.11.2025
TLX
LISTED
ASX
ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®1, 89Zr-DFO-girentuximab) PET/CT2 would have undergone a change in clinical management,...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
TLX
LISTED
ASX
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Telix Pharmaceuticals Limited (TLX) Shareholders To Inquire About Securities Fraud Class Action
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) securities between February 21, 2025 and August 28, 2025, inclusive...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
TLX
LISTED
ASX
Telix Pharmaceuticals Limited (TLX) Faces Securities Class Action Amid SEC Subpoena, Complete Response Letter -- Hagens Berman
News Preview
Telix Pharmaceuticals Limited (NASDAQ: TLX), a commercial-stage biopharmaceutical company focused on medical imaging and therapeutic radiopharmaceuticals, is now the target of a securities class action lawsuit, capping a tumultuous several months that saw the company's stock crater following revelations of a regulatory subpoena and an FDA rejectio...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
TLX
LISTED
ASX
Law Offices of Howard G. Smith Encourages Telix Pharmaceuticals Limited (TLX) Shareholders To Inquire About Securities Fraud Class Action
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) securities between February 21, 2025 and August 28, 2025, inclusive (the “Class Period”). Telix investors have until January 9, 2025 to file a lead plaintiff...
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2025
TLX
LISTED
ASX
Telix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – TLX
News Preview
The DJS Law Group reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of TLX duri...
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2025
TLX
LISTED
ASX
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) and reminds investors of the January 9, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
F...
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2025
TLX
LISTED
ASX
TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commissio...
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2025
TLX
LISTED
ASX
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Telix Pharmaceuticals Ltd. Investors – TLX
News Preview
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Telix investors under the federal s...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
05.11.2025
TLX
LISTED
ASX
Telix to Participate in UBS and Jefferies Global Healthcare Conferences
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will participate in the upcoming UBS Global Healthcare Conference in Palm Beach, FL (U.S.) and in the Jefferies Global Healthcare Conference in London (UK)....
Themefolio
Profiler
Peergroup
© PR Newswire
23.10.2025
TLX
LISTED
ASX
TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today welcomes updated guidelines from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Nuclear Medicine (EANM) and The American College of...
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2025
TLX
LISTED
ASX
Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090 (153Samarium (Sm)-DOTMP), a therapeutic radiopharmaceutical candidate for treating pain asso...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
TLX
LISTED
ASX
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated otherwise....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
TLX
LISTED
ASX
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated otherwise....
Themefolio
Profiler
Peergroup
© PR Newswire
01.10.2025
TLX
LISTED
ASX
Telix Announces Record-Breaking Presence at EANM 2025
News Preview
MELBOURNE, Australia, Sept. 30, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its record-breaking conference presence with 28 company-related abstract presentations at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held i...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2025
TLX
LISTED
ASX
CMS Grants Transitional Pass-Through Status for Gozellix
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for Gozellix® (kit for the preparation of gallium-68 (6...
Themefolio
Profiler
Peergroup
© PR Newswire
10.09.2025
TLX
LISTED
ASX
Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation of gallium-68 (68Ga) gozetotide injection) to inclu...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.09.2025
TLX
LISTED
ASX
Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation of gallium-68 (68Ga) gozetotide injection) to i...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.08.2025
TLX
LISTED
ASX
Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 4:50 p.m. ET on Monday, September 8, 2025 (6:50 a.m. AEST, Sep 9) and at the H.C. Wainwright 27th Annual Global Investment Conference...
Themefolio
Profiler
Peergroup
© BusinessWire
22.08.2025
TLX
LISTED
ASX
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation – TLX
News Preview
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public.
So What: If you purchased Telix securitie...
Themefolio
Profiler
Peergroup
© BusinessWire
21.08.2025
TLX
LISTED
ASX
Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – TLX
News Preview
The DJS Law Group announces that it is investigating claims on behalf of investors of Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.08.2025
TLX
LISTED
ASX
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise....
Themefolio
Profiler
Peergroup
© BusinessWire
31.07.2025
TLX
LISTED
ASX
TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or fai...
Themefolio
Profiler
Peergroup
© PR Newswire
30.07.2025
TLX
LISTED
ASX
Telix H1 2025 Results: Investor Webcast Notification
News Preview
MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.07.2025
TLX
LISTED
ASX
Telix H1 2025 Results: Investor Webcast Notification
News Preview
MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025....
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
TLX
LISTED
ASX
Securities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
TLX
LISTED
ASX
Telix Pharmaceuticals Limited (TLX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TELIX PHARMACEUTICALS LIMITED (TLX), CONTACT THE LAW OFFICES OF HOWARD G. SM...
Themefolio
Profiler
Peergroup
© BusinessWire
23.07.2025
TLX
LISTED
ASX
Securities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
News Preview
The Law Offices of Frank R. Cruz announces an investigation of Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON TELIX PHARMACEUTICALS LIMITED (TLX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY...
Themefolio
Profiler
Peergroup
© PR Newswire
22.07.2025
TLX
LISTED
ASX
Telix Reports $204M Revenue, Up 63% YOY
News Preview
MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.07.2025
TLX
LISTED
ASX
Telix Reports $204M Revenue, Up 63% YOY
News Preview
MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise....
Themefolio
Profiler
Peergroup
© PR Newswire
20.07.2025
TLX
LISTED
ASX
Prostatakrebs-PSMA-PET-Bildgebungsmittel Illuccix® in Österreich zugelassen
News Preview
MELBOURNE, Australien, 20. Juli 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, „Telix") gibt heute bekannt, dass sein Prostatakrebs-PET[1] -Bildgebungsmittel Illuccix® (Kit zur Herstellung einer Gallium-68-Gozetotid-Injektion) vom BASG[2] die Zulassung für den Nachweis und die Lokalisierung von Prostata-spezifischen Me...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2025
TLX
LISTED
ASX
Gozellix Receives Permanent HCPCS Code
News Preview
MELBOURNE, Australia and INDIANAPOLIS, July 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that its next-generation PSMA1 PET2 imaging agent, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), has been granted a permanent Healthcare Common Procedure Coding Sy...
Themefolio
Profiler
Peergroup
© PR Newswire
09.07.2025
TLX
LISTED
ASX
Gozellix Receives Permanent HCPCS Code
News Preview
MELBOURNE, Australia, July 9, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that its next-generation PSMA[1] PET[2] imaging agent, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), has been granted a permanent Healthcare Common Procedure Coding System (HCPCS) code...
Themefolio
Profiler
Peergroup
© PR Newswire
25.06.2025
TLX
LISTED
ASX
Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses
News Preview
MELBOURNE, Australia and INDIANAPOLIS, June 25, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its Telix Manufacturing Solutions (TMS) facility in Brussels South (Seneffe), Belgium, has produced its first Good Manufacturing Practice (GMP)-grade commercial radiopharmaceutical...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.06.2025
TLX
LISTED
ASX
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
News Preview
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved a label expansion for Illuccix® (kit for the preparation of gallium Ga-68 gozetotide, for injection) to...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2025
TLX
LISTED
ASX
Telix Precision Medicine Announces AlFluor Radiochemistry Platform
News Preview
MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces it has launched a novel PET1 radiochemistry solution based on 18F-aluminium fluoride (AlF), named AlFluor™....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2025
TLX
LISTED
ASX
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
News Preview
MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces five abstract presentations and two satellite symposia featuring its developmental theranostic programs and commercial products at the Society of Nuclear Medicine and Molecular Imag...
Themefolio
Profiler
Peergroup
© PR Newswire
13.06.2025
TLX
LISTED
ASX
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Greece
News Preview
MELBOURNE, Australia, June 13, 2025 /PRNewswire/ --Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by the Greek EOF[2] for the detection and loc...
Themefolio
Profiler
Peergroup
© PR Newswire
11.06.2025
TLX
LISTED
ASX
Telix Illuccix® PSMA-PET-Bildgebungsmittel in Deutschland zugelassen
News Preview
MELBOURNE, Australien, 11. Juni 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, „Telix", „Unternehmen") gibt heute bekannt, dass sein bildgebendes Mittel Illuccix® (Kit zur Herstellung einer Gallium-68-Gozetotid-Injektion) für Prostatakrebs-PET[1] in Deutschland vom BfArM[2] die Zulassung für den Nachweis und die Lokali...
Themefolio
Profiler
Peergroup
© PR Newswire
05.06.2025
TLX
LISTED
ASX
Telix's Illuccix® PSMA-PET Imaging Agent Approved in Germany
News Preview
MELBOURNE, Australia, June 5, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Germany by BfArM[2] for the detection an...
Themefolio
Profiler
Peergroup
© PR Newswire
04.06.2025
TLX
LISTED
ASX
Telix's Illuccix® PSMA-PET Imaging Agent Approved in Portugal
News Preview
MELBOURNE, Australia, June 4, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Portugal by INFARMED[2] for the detectio...
Themefolio
Profiler
Peergroup
© PR Newswire
04.06.2025
TLX
LISTED
ASX
Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan
News Preview
MELBOURNE, Australia and KYOTO, Japan, June 4, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that it has established Telix Manufacturing Solutions (TMS) in Yokohama, Japan. Telix's first cyclotron facility in the Asia Pacific region represents a significant milestone in the Comp...
Themefolio
Profiler
Peergroup
© PR Newswire
20.05.2025
TLX
LISTED
ASX
Telix at ANZSNM Annual Scientific Meeting 2025
News Preview
MELBOURNE, Australia, May 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces a strong presence at the 55th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM ASM 2025), to be held in Melbourne, Australia from 23–25 May 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
13.05.2025
TLX
LISTED
ASX
Illuccix China Phase 3 Study Completes Enrolment
News Preview
MELBOURNE, Australia and INDIANAPOLIS, May 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that the pivotal Phase 3 registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging in Chinese patients has completed patient enrol...
Themefolio
Profiler
Peergroup
© PR Newswire
07.05.2025
TLX
LISTED
ASX
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
News Preview
MELBOURNE, Australia and INDIANAPOLIS, May 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in Thyroid, the official journal of the American Thyroid Association. The candidate demons...
Themefolio
Profiler
Peergroup
© PR Newswire
05.05.2025
TLX
LISTED
ASX
Telix's Illuccix® PSMA-PET Imaging Agent Approved in the Czech Republic
News Preview
New approval provides hospitals and clinics in the Czech Republic with access to a proven PSMA-PET imaging agent
MELBOURNE, Australia, May 5, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent, Illuccix® (kit for the preparation of gallium-68...
Themefolio
Profiler
Peergroup
© PR Newswire
30.04.2025
TLX
LISTED
ASX
Illuccix Prostate Cancer PSMA-PET Imaging Agent Approved in Finland
News Preview
MELBOURNE, Australia, April 30, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by Fimea[2] for the detection and localization...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.04.2025
TLX
LISTED
ASX
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
News Preview
New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.04.2025
TLX
LISTED
ASX
Telix Reports US$186M Q1 Revenue, Up 62% YOY
News Preview
Telix Pharmaceuticals reported strong Q1 2025 revenue of $186 million, up 62% year-on-year, driven by Illuccix® sales and RLS Radiopharmacies acquisition....
Themefolio
Profiler
Peergroup
© PR Newswire
16.04.2025
TLX
LISTED
ASX
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
News Preview
MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 s...
Themefolio
Profiler
Peergroup
© PR Newswire
16.04.2025
TLX
LISTED
ASX
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
News Preview
MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 stud...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.04.2025
TLX
LISTED
ASX
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
News Preview
MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan1) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 st...
Themefolio
Profiler
Peergroup
© PR Newswire
15.04.2025
TLX
LISTED
ASX
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Sweden
News Preview
MELBOURNE, Australia, April 15, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by the Swedish MPA[2] for the detection and loc...
Themefolio
Profiler
Peergroup
© PR Newswire
07.04.2025
TLX
LISTED
ASX
Telix Appoints Paul Schaffer as Chief Technology Officer
News Preview
MELBOURNE, Australia and INDIANAPOLIS, April 7, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today. ...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.04.2025
TLX
LISTED
ASX
Anne Whitaker Appointed as Non-Executive Director
News Preview
MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251....
Themefolio
Profiler
Peergroup
© PR Newswire
01.04.2025
TLX
LISTED
ASX
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
News Preview
MELBOURNE, Australia, April 2, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that a first patient has been dosed in the Phase 1 ZOLAR[1] trial of TLX300-CDx (89Zr-olaratumab) in patients with advanced, metastatic soft tissue sarcoma (STS) at the Melbourne Theranostic Innovation Cent...
Themefolio
Profiler
Peergroup
© PR Newswire
21.03.2025
TLX
LISTED
ASX
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
News Preview
MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetot...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
